However, another phase II clinical trial involving 86 patients with BC showed that platinum-based monotherapy was used in the treatment of first-line or second-line metastatic BC, and patients with p63 gene mutations did not show a higher pCR, RFS, and OS [44]. Here, TP63 is linked to breast cancer.